Novartis Release

| Source: Novartis Pharma AG Novartis Pharma AG

EMEA updates Zometaâ label to include longer-term efficacy data on prevention of bone complications in advanced cancers
 
  •          Breast cancer patients have additional 20% reduced risk of bone complications with Zometa compared to pamidronate
  •          Long term safety and efficacy of Zometa confirmed by these data
    •  
    Basel, 12 June 2003 - Novartis announced today that it has received approval from the European Agency for the Evaluation of Medicinal Products (EMEA) to expand the current marketing authorization for Zometa® (zoledronic acid) to include data on long-term treatment for patients with advanced cancers that have spread to the bone.
     
    Please see full press release under the following link:
     

    Attachments

    Media Release